Drug intelligence / Profile preview

CC210F

Development stage: Preclinical
Lead developer: 环码生物
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CC210F is a circular RNA (circRNA) vaccine candidate being developed by Shanghai CirCode Biomed. Utilizing the company's proprietary circular RNA platform, the vaccine is designed to provide more stable and long-lasting protein expression compared to traditional linear mRNA vaccines. CC210F is currently in the preclinical stage of development and is part of a pipeline focused on infectious diseases and therapeutic proteins. The circular structure of the RNA molecule inherently resists exonuclease-mediated degradation, potentially allowing for lower dosing and improved thermal stability.

Beyond the preview

Go deeper on CC210F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC210F.

Explore the full profile